Physician profile
Brandon E Guth
NPI 1629587282
$11,189.63
in general payments reported to CMS, 2019-2025
27 companies · $5,456 in 2025
The $5,456 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $461 · 2022: $695 · 2023: $1,131 · 2024: $3,447 · 2025: $5,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,225 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Education: $59.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,224.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Education | $59.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,098.11 | 2021-2025 | |
| Lilly USA, LLC | $686.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $667.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $523.74 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $357.37 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $314.59 | 2021-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $302.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $272.63 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.75 | 2021-2025 | Jardiance, Stiolto Respimat |
| Abbott Laboratories | $205.85 | 2023-2025 | Freestyle Libre 3, Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $200.69 | 2021-2025 | Trintellix |
| Gilead Sciences, INC. | $183.28 | 2021-2025 | |
| Lundbeck LLC | $182.98 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $166.53 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $141.22 | 2025 | Fanapt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $103.17 | 2023-2025 | |
| Indivior INC. | $93.36 | 2024-2025 | Sublocade |
| Astellas Pharma US INC | $88.56 | 2025 | Veozah |
| Exact Sciences Corporation | $78.40 | 2023-2025 | Cologuard Collection Kit |
| Corium, LLC | $69.45 | 2022-2025 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.34 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $53.76 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $36.10 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $29.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.20 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Guth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.